ALCHEMIA LIMITED(ACL)

The suspension of trading in the securities of Australian Primary Hemp Limited will lift and the company reinstated to official quotation at the commencement of trading on Friday, 18 October 2019 at 10:00am AEDT, following its re-compliance with Chapters 1 and 2 of the ASX Listing Rules. The company raised $5,700,000 pursuant to the offer under its replacement prospectus dated 16 September 2019 by the issue of 28,500,000 at an issue price of $0.20 per share.

name changed to Australian Primary Hemp Limited

The offers in the replacement prospectus have now closed. The company has successfully raised $5,700,000 through the issue of 28,500,000 fully paid ordinary shares at $0.20 per share. Completion of the share sale agreement between the company, ACN 614 061 951 Pty Ltd and hte shareholders of APH with respect to the acquisition of 100% of the issued capital in APH by the company has now occurred. The company has issued 15,225,000 fully paid ordinary shares to the shareholders of APH as consideration in accordance with the share sale agreement.

The company has completed the consolidation of its share capital on a one (1) for twenty (20) basis. The consolidation was approved by shareholders at the AGM held on 16 September 2019. The post-consolidation shares of the company are as follows: fully paid ordinary shares - 324,723,621 (pre) - 16,234,845 (post). The consolidation will take effect from 27 September 2019.

we understand that on or about this date the company consolidated its shares 1 for 20

The company releases a replacement prospectus to acquire fully paid ordinary shares in Alchemia Limited.

The company releases the results of its annual general meeting.

The company releases a notification of consolidation of its securities. Shareholders will get 1 share for every 20 presently owned.

The company's AGM will be held at Holding Redlich Lawyers, Level 8, 555 Bourke Street, Melbourne VIC 3000 on Monday, 16 September 2019 commencing at 10:00am (Melbourne time).

The company releases its Appendix 4G and Corporate Governance Statement.

The company lodges its Appendix 4E and 2019 Annual Report.

The company lodges an Appendix 4C - Quarterly.

The company has entered into a share sale agreement pursuant to which it has conditionally agreed to acquire 100% of the issued capital of Australian Primary Hemp. APH is one of Australia's leading hemp producers with a demonstrated execution capability and diversified business operations across the value chain, owning quality production assets in Victoria. APH has a vast network of growers across the east coast of Australia with large scale hemp production capability. Since inception APH's network of growers have procured over 500T of hemp grain. Since the legalisation of hemp in Australia, the industry has experienced rapid growth and APH is strongly positioned to benefit from the growth in hemp demand in Australia and internationally. "¢ Incoming APH executive team and Board of Directors have significant agricultural and hemp industry experience. Alchemia will change its name to "Australian Primary Hemp Limited" on settlement of the acquisition.

The extension of the voluntary suspension is requested pending an announcement regarding a proposed change to the nature and scale of the company's activities and ASX's determination as to the application of Listing Rule 11.1 to that transaction. The company requests that the voluntary suspension remains in place until the earlier of the commencement of normal trading on Monday, 1 July 2019, or when an announcement with regard to ASX's determination is released to the market.

The extension of the voluntary suspension is requested pending an announcement regarding a proposed change to the nature and scale of the Company's activities and ASX's determination as to the application of Listing Rule 11.1 to that transaction. The Company requests that the voluntary suspension remains in place until the earlier of the commencement of normal trading on Monday, 3 June 2019, or when an announcement with regard to ASX's determination is released to the market.

The company lodges its Appendix 4C - Quarterly.

The securities of Alchemia Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of ACL, pending the release of an announcement regarding a proposed change to the nature and scale of the Company's activities.

The suspension of trading in the securities of Alchemia Limited will be lifted immediately, following the receipt of additional information about the ongoing activities of the Company.

The company provides an update on company activities.

The company advises that the ASX has suspended trading of the Company's securities effective close of trading on Tuesday 14 June 2016 due to ASX's opinion that the Company is not in compliance with ASX Listing Rule 12.1. The Company has this morning provided a submission to the ASX to demonstrate its ongoing compliance with Chapter 12 and specifically 12.1 of the Listing Rules. The ASX is currently in the process of reviewing this submission.

The securities ofAlchemia Limited (the "Company")will be suspended from quotation at the close oftrading today, Tuesday, 14 June 2016 in accordance with listing rule 17.3, as ASX has determined that the Company does not have sufficient operations to warrant the continued quotation of its securities in accordance with listing rule 12.1. The suspension will continue until either the Company is able to demonstrate compliance with Chapter 12 of the Listing Rules, or it complies with Chapters 1 and 2 of the Listing Rules.

we understand that on or about this date the company made a capital return of 9.3 cents per share

we understand that on or about this date the company made a capital return of 9.3 cents per share

The suspension of trading in the securities of Alchemia Limited (the "Company") will be lifted immediately, following receipt of an announcement regarding the Company's profit share on sales of its generic anti-coagulant drug fondaparinux for the quarter ending 31 March 2015. Security Code: ACL

The company releases its Fondaparinux Result for Quarter Ended 31 March 2015.

The securities of Alchemia Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement regarding its profit share on sales of its generic anti-coagulant drug fondaparinux for the quarter ending 31 March 2015. Security Code: ACL

The suspension of trading in the securities of Alchemia Limited (the "Company") will be lifted immediately, following the Company" update in relation to the proposed demerger of Audeo Oncology, Inc. from the Company. Security Code: ACL

The securities of Alchemia Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, whilst it continues negotiations relating to the demerger of Audeo Oncology, Inc. from the Company. Security Code: ACL Adrian Smythe

we understand that on or about this date the company undertook, proposed to undertake or was the subject of the following corporate action: - demerge its wholly owned subsidiary Alchemia Oncology Pty Ltd - this corporate event may appear elsewhere in this company record